Home/News & Press/Medical Fairs/NEW PRODUCT! CACLP 2023 Witnessed Our Impression
NEW PRODUCT! CACLP 2023 Witnessed Our Impression
May 31,2023 (Edit) Wondfo
On May 28, the 20th China Association of Clinical Laboratory Practice Expo (CACLP) was unveiled in Nachang, Jiangxi Province of China. On the first morning of the expo, Wondfo launched a new product—Ucare-6000 Automatic Blood Gas Biochemical Analyzer. Its efficiency, flexibility, accuracy and simplified operation make it the focus of the site. Meanwhile, the expo witnessed the display of Wondfo’s all product platforms, which attracted many professionals.


Efficient & Flexible, Accurate & Simplified, It is Wondfo’s new product

As a newly launched, powerful product of electrochemistry platform, Ucare-6000 Automatic Blood Gas Biochemical Analyzer enjoys efficiency and flexibility as well as accuracy and simplified operation. Based on the existing technology of electrochemistry platform—electrochemistry sensing technology and microfluidic technology—it adopts thin-film microelectrode technology. Without pipeline in the instrument, it is easy in maintenance. Moreover, the sound QC system allows automatic calibration and internal QC so as to ensure accurate result. 

Integration of test cartridge and reagent bag. Ucare-6000 integrates the electrode cartridge with reagent bag, which makes the testing easier and safer. Results of all 34 parameters are delivered with one-step sample loading and convenient operation with user-friendly touch screen. Furthermore, the integrated electrode cartridge and reagent bag enable repeated testing, reducing cost of individual test cartridge.

Long shelf life of reagent bag. Reagent bag is room-temperature stable for 7 months and valid for 30 days after loading.

Built-in battery with hours of battery life. The compact instrument is equipped with barcode scanner for convenient information input with no need for external scanner. The built-in battery allows continuous testing of 80 samples and long standby. Internal QC monitors the system regularly to ensure accurate and stable performance.

Ucare-6000’s test reports include 24 calculated parameters of blood gas, electrolytes, metabolites and Hct. Moreover, the test menu supports expansion with BUN, CRE, etc. based on practical need. Paired with BGA-102 blood gas analyzer, Ucare-6000 is flexibly applicable in various scenarios such as emergency, ICU, obstetrics and gynecology, pediatrics, operating room, respiratory department, etc.

Impressive Cardiovascular Testing Solution Covers All Cardiovascular Biomarkers

On May 29, Wondfo held a roadshow of the total solution for cardiometabolic diseases. According to the "China Cardiovascular Health and Disease Report 2021" issued by the National Center for Cardiovascular Diseases, the number of cardiovascular patients in China is on the rise. It is estimated that there are 330 million people with cardiovascular diseases around the country, including 245 million people with hypertension and 13 million people with stroke, 11.39 million with coronary heart disease, and 8.9 million with heart failure.

Regarding hypertension, which is the core of prevention and treatment of cardiovascular and cerebrovascular diseases in China, Wondfo, based on the chemiluminescence platform, provides sensitive detection of six hypertension items (ACTH, Cortisol, Renin, AI, A II, ALD), which help improve patient diagnosis, awareness and treatment, and so as to improve patient prognosis.

The hs-cTnI from two platforms—immunofluorescence and chemiluminescence—launched by Wondfo can shorten the duration for acute myocardial infarction (AMI) diagnosis and improve identification of myocardial infarction and unstable angina.

According to the "Chinese Expert Consensus 2022 on the Clinical Application of Biomarkers for Heart Failure", Wondfo provides a whole-process management solution for heart failure, covering heart failure prediction, diagnosis, evidence for treatment and prognosis assessment.

In response to the governmental and social needs for cardiovascular disease detection, Wondfo continues to improve the product panel for cardiovascular disease detection. There are over 20 items such as hs-cTnI, NT-proBNP, BNP, sST2, etc., covering all markers for cardiovascular diseases.

Currently, Wondfo has immunoassay, biochemistry, instant coagulation and other platforms in detecting cardiovascular diseases, which are simple in operation and rapid in delivering results. Wondfo's cardiovascular detection solution can not only help clinical departments in the identification and diagnosis of cardiovascular diseases, risk stratification, treatment assessment, drug monitoring and risk assessment, but also fit in scenarios of different volumes—such as outpatient and emergency laboratory, cardiology, respiratory department, ICU, etc.—allowing flexible customization according to features of different technology platforms, so as to achieve a triangular balance of cost, efficiency, and accuracy.

A Comprehensive Display of All Products from All Platforms

With 30-year experience dedicated to in vitro diagnostics, Wondfo has developed 9 technology platforms, multiple products and various scenario-targeted solutions. We offer testing solutions for acute and critical cases, inflammation, coagulation primary care, chest pain center, pathology detection as well as intellectual management system. In the 20th CACLP, Wondfo displayed all products from all platforms, attracting attentions from many.

Dedicated to make biology technology benefit the public, Wondfo strives for excellence with continuous efforts for the better, so as to improve the efficiency of diagnosis in medical institutions and to safeguard people’s health and happiness.
This website uses cookies. By continuing to browse or by clicking “Accept”, you agree to our use of cookies to enhance your experience.

Choose your location

It looks like you are located in: Spain
You are trying to view a page from a different country or region. *Not all products and services may be available in your country or region.